Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed
Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.
Axinn Announces Nominations for the Concurrences 2026 Antitrust Writing Awards
Axinn is pleased to announce that three written pieces authored by our lawyers have been nominated for the Concurrences 2026 Antitrust Writing Awards.
2025 Healthcare Antitrust Enforcement Wrap Up
On January 28, Axinn hosted a Healthcare Antitrust Year-In-Review CLE webinar, presented by counsel Carol Liu and Monica Smith, and associates Tasneem Chowdhury and Kaitlin Rittgers, and moderated by partner Lisl Dunlop, reviewing the most significant antitrust developments that shaped the healthcare industry in 2025 and providing practical insights into what those developments mean for the industry heading into 2026.
Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed
Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.
Axinn Announces Nominations for the Concurrences 2026 Antitrust Writing Awards
Axinn is pleased to announce that three written pieces authored by our lawyers have been nominated for the Concurrences 2026 Antitrust Writing Awards.
2025 Healthcare Antitrust Enforcement Wrap Up
On January 28, Axinn hosted a Healthcare Antitrust Year-In-Review CLE webinar, presented by counsel Carol Liu and Monica Smith, and associates Tasneem Chowdhury and Kaitlin Rittgers, and moderated by partner Lisl Dunlop, reviewing the most significant antitrust developments that shaped the healthcare industry in 2025 and providing practical insights into what those developments mean for the industry heading into 2026.
Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed
Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.
Insights
